Loading people...
Billy Deitch is a Partner at Oak HC/FT, a prominent venture and growth equity firm. He is an investor specializing in healthcare technology, fintech, and insurtech, known for identifying and supporting innovative companies.
Billy Deitch primarily invests in companies within the healthcare technology, financial technology (fintech), and insurtech sectors. He focuses on high-growth opportunities and disruptive innovations in these areas.
Billy Deitch works as a Partner at Oak HC/FT, a leading venture and growth equity firm. The firm has offices in Stamford, CT, and New York, NY.
Billy Deitch is a Partner at Oak HC/FT based in San Francisco, California, where he focuses on growth equity and early-stage venture investments in the healthcare sector. Before joining the firm in 2018 and becoming a Partner in 2022, he worked as an investor at Francisco Partners and TPG Growth, and began his career in investment banking at UBS and Evercore. He holds a Bachelor of Arts in Economics from Yale University and a Master of Business Administration from the Stanford Graduate School of Business. Deitch currently holds board director or observer roles at several high-growth startups, including DispatchHealth, Main Street Health, which raised a $315 million round in 2023, and Vesta Healthcare, which secured a $65 million Series C in 2024. His current focus centers on backing tech-enabled healthcare services, value-based care models, and healthcare software companies.
Billy Deitch is a highly respected Partner at Oak HC/FT, a prominent venture and growth equity firm known for its deep expertise in healthcare and financial technology. As a key member of the investment team, Billy Deitch focuses on identifying and nurturing innovative companies that are poised to disrupt their respective industries. His investment thesis centers on high-growth opportunities within healthcare technology, fintech, and insurtech, where he leverages his extensive industry knowledge to back visionary founders.
At Oak HC/FT, Billy Deitch is instrumental in the firm's mission to invest in and build market-leading businesses. He is actively involved in all stages of the investment process, from initial due diligence and deal sourcing to post-investment strategic guidance. His work with portfolio companies often involves helping them scale operations, refine business models, and navigate complex market landscapes, ensuring they achieve their full potential. Billy Deitch's strategic involvement helps these companies not only secure funding but also gain critical operational and market insights.
Before joining Oak HC/FT in 2017, Billy Deitch honed his financial acumen and strategic insights at Goldman Sachs. There, he worked in the Technology, Media & Telecom (TMT) investment banking division, advising a diverse range of companies on mergers, acquisitions, and capital market transactions. This experience provided him with a robust understanding of market dynamics and corporate finance, which he now applies to his venture capital endeavors. Prior to Goldman Sachs, Deitch also gained valuable analytical experience at Bridgewater Associates, a leading hedge fund. He is an alumnus of the University of Pennsylvania's Wharton School, where he earned his degree.
Billy Deitch's portfolio involvement includes significant contributions to companies like Komodo Health, a leader in healthcare data analytics; Vesta Healthcare, focused on in-home care solutions; and Galileo, a modern digital banking platform. These investments exemplify his commitment to backing companies that are not only financially promising but also have the potential to create substantial positive impact in their sectors. His strategic guidance helps these companies navigate growth challenges and capitalize on emerging opportunities, solidifying their market positions.
Through his work, Billy Deitch continues to solidify Oak HC/FT's position as a top-tier investor in the rapidly evolving healthcare and financial technology landscapes. His dedication to fostering innovation and supporting entrepreneurial talent makes him a pivotal figure in the venture capital community. Investors and founders alike recognize his ability to identify groundbreaking technologies and build enduring value, driving significant returns and industry advancement.
